Style | Citing Format |
---|---|
MLA | Yadollahi Farsani M, et al.. "Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer." Cancer Reports, vol. 7, no. 2, 2024, pp. -. |
APA | Yadollahi Farsani M, Amini Farsani Z, Teimuri S, Kolahdouzan M, Eshraghi Samani R, Teimori H (2024). Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer. Cancer Reports, 7(2), -. |
Chicago | Yadollahi Farsani M, Amini Farsani Z, Teimuri S, Kolahdouzan M, Eshraghi Samani R, Teimori H. "Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer." Cancer Reports 7, no. 2 (2024): -. |
Harvard | Yadollahi Farsani M et al. (2024) 'Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer', Cancer Reports, 7(2), pp. -. |
Vancouver | Yadollahi Farsani M, Amini Farsani Z, Teimuri S, Kolahdouzan M, Eshraghi Samani R, Teimori H. Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer. Cancer Reports. 2024;7(2):-. |
BibTex | @article{ author = {Yadollahi Farsani M and Amini Farsani Z and Teimuri S and Kolahdouzan M and Eshraghi Samani R and Teimori H}, title = {Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer}, journal = {Cancer Reports}, volume = {7}, number = {2}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Yadollahi Farsani M AU - Amini Farsani Z AU - Teimuri S AU - Kolahdouzan M AU - Eshraghi Samani R AU - Teimori H TI - Deregulation of Mir-1245B-5P and Mir-92A-3P and Their Potential Target Gene, Gata3, in Epithelial–Mesenchymal Transition Pathway in Breast Cancer JO - Cancer Reports VL - 7 IS - 2 SP - EP - PY - 2024 ER - |